| __timestamp | Ligand Pharmaceuticals Incorporated | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 12122000 | 1271353000 |
| Thursday, January 1, 2015 | 13380000 | 1620577000 |
| Friday, January 1, 2016 | 21221000 | 2052295000 |
| Sunday, January 1, 2017 | 26887000 | 2075142000 |
| Monday, January 1, 2018 | 27863000 | 2186100000 |
| Tuesday, January 1, 2019 | 55908000 | 3036600000 |
| Wednesday, January 1, 2020 | 59392000 | 2735000000 |
| Friday, January 1, 2021 | 69012000 | 2908100000 |
| Saturday, January 1, 2022 | 36082000 | 3592500000 |
| Sunday, January 1, 2023 | 24537000 | 4439000000 |
| Monday, January 1, 2024 | 5132000000 |
Igniting the spark of knowledge
In the competitive world of pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Regeneron Pharmaceuticals, Inc. and Ligand Pharmaceuticals Incorporated have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Regeneron consistently allocated a significant portion of its resources to R&D, with expenditures peaking at approximately $4.4 billion in 2023. This represents a staggering 250% increase from 2014, underscoring Regeneron's aggressive pursuit of new therapies.
Conversely, Ligand Pharmaceuticals maintained a more conservative approach, with R&D spending reaching its highest at around $69 million in 2021. Despite this, Ligand's strategic focus on niche markets and partnerships has allowed it to remain competitive. This divergence in R&D investment strategies highlights the varied paths companies can take to achieve success in the pharmaceutical industry.
R&D Spending Showdown: Regeneron Pharmaceuticals, Inc. vs Insmed Incorporated
R&D Spending Showdown: Regeneron Pharmaceuticals, Inc. vs Viatris Inc.
Comparing Innovation Spending: Regeneron Pharmaceuticals, Inc. and Verona Pharma plc
Regeneron Pharmaceuticals, Inc. or Jazz Pharmaceuticals plc: Who Invests More in Innovation?
R&D Insights: How Regeneron Pharmaceuticals, Inc. and PTC Therapeutics, Inc. Allocate Funds
Comparing Innovation Spending: Regeneron Pharmaceuticals, Inc. and Dynavax Technologies Corporation
Research and Development Expenses Breakdown: argenx SE vs Ligand Pharmaceuticals Incorporated
R&D Insights: How CymaBay Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated Allocate Funds
R&D Insights: How HUTCHMED (China) Limited and Ligand Pharmaceuticals Incorporated Allocate Funds
Analyzing R&D Budgets: Ligand Pharmaceuticals Incorporated vs Galapagos NV
Analyzing R&D Budgets: Ligand Pharmaceuticals Incorporated vs Celldex Therapeutics, Inc.
R&D Insights: How Ligand Pharmaceuticals Incorporated and Travere Therapeutics, Inc. Allocate Funds